Financial Performance - Segment Operating Income (SOI) was $159 million[1], impacted by challenging industry dynamics[3] - Net sales reached $4,465 million, a decrease of 2.3% year-over-year (YoY)[11] - The company reported a net loss of $0.17 per share[11] - Free cash flow was negative $387 million, a decrease of 11.8% YoY[11] - Gross margin was 17%, a decrease of 3.6 percentage points YoY[23] Strategic Initiatives - Goodyear Forward initiatives drove benefits of $195 million in Q2 2025[3], with $395 million achieved in the first six months of 2025[15] - The company expects an additional $750 million benefit from Goodyear Forward in 2025[15] - Gross asset sale proceeds to date totaled $1.6 billion, with expectations to exceed $2.0 billion this year[3] Segment Results - Americas segment operating income was $141 million, with a margin of 5.3%[13] - EMEA segment reported a segment operating loss of $25 million, with a margin of -1.9%[13] - Asia Pacific segment operating income was $43 million, with a margin of 9.4%[13] Outlook - The company anticipates global unit volumes to decrease by approximately 5% in Q3 2025[42] - Goodyear Forward is expected to contribute a benefit of approximately $180 million in Q3 2025[42]

Financial Performance Highlights - Arcosa's Adjusted EBITDA grew by 42%, outpacing revenue growth of 18%[9] - The company achieved a record consolidated Adjusted EBITDA Margin of 20.9%, an increase of 360 basis points[9] - Pricing in aggregates increased by 8%, leading to a 15% gain in cash unit profitability[9] - Q2 2025 revenues increased by 18% from $626.6 million to $736.9 million[20] - Adjusted EBITDA increased by 37% from $112.7 million to $154.2 million[20] Strategic Initiatives and Outlook - Arcosa is targeting a long-term net leverage ratio of 2.0-2.5x within the next three quarters[9] - The company maintains full-year revenue guidance, anticipating a 17% increase[9] - Adjusted EBITDA is expected to increase by 30%[9] - The company expects Adjusted EBITDA growth to be roughly 40% organic and 60% inorganic[9] Segment Performance - Construction Products' Adjusted Segment EBITDA increased by 44% from $69.7 million to $100.4 million[23] - Engineered Structures' Adjusted Segment EBITDA increased by 31% from $41.7 million to $54.8 million[26] - Transportation Products' revenues increased by 18%[28]

Financial Performance - Kingstone's core direct written premium grew by 17% compared to Q2 2024[6] - Net investment income increased by 30% compared to Q2 2024, with an average portfolio yield of 393%[6] - The company's combined ratio improved to 715% in Q2 2025, compared to 782% in Q2 2024[70] - Adjusted EBITDA increased by 884% to $14783 thousand in Q2 2025, compared to $7845 thousand in Q2 2024[70] - Net income rose by 1492% to $11252 thousand in Q2 2025, compared to $4515 thousand in Q2 2024[70] Strategic Initiatives - Kingstone's "Select" product has a ~31% lower frequency than the "Legacy" product, indicating improved risk selection[18] - Select policies represent 48% of policies in force as of June 30, 2025[18] - The company achieved a NY growth of +31% in FY2024[49] - Kingstone estimates approximately $12 million in premiums from the AmGuard renewal rights transaction, beginning September 1, 2025[47] Future Outlook - Kingstone anticipates net premiums earned of ~$187 million for fiscal year 2025[51] - The company aims to reach ~$500 million in direct premiums written by 2029[57]

Financial Performance - AQN's Net Earnings decreased by 90% to $17.4 million, compared to $180.1 million in the same period of the previous year[24] - AQN Adjusted Net Earnings decreased by 13% to $36.2 million, compared to $41.5 million in the same period of the previous year[24] - Adjusted Net Earnings per share decreased by 33% to $0.04, compared to $0.06 in the same period of the previous year[24] - Dividends per share declared to common shareholders decreased by 40% to $0.0650, compared to $0.1085 in the same period of the previous year[24] Rate Case Updates - BELCO was authorized an increase of $33.6 million out of a rate request of $59.1 million, implemented retroactively to Jan 1, 2024[38] - Granite State Electric was authorized an increase of $5.5 million out of a rate request of $15.5 million, implemented on April 1, 2025[38] - Midstates Gas in Missouri was authorized an increase of $9.1 million out of a rate request of $13.2 million, implemented on Jan 8, 2025[38] - Missouri Water was authorized an increase of $6.2 million out of a rate request of $8.1 million, implemented on Mar 1, 2025[38] - Various Water & Wastewater in Arizona was authorized an increase of $4.2 million out of a rate request of $6.0 million, implemented on July 1, 2025[38] Key Credit Adjustment Figures - S&P and Fitch selected debt adjustments include a deduction of $700 million for equity credit (50% of $1.4 billion hybrids) and $300 million for Empire securitization, with an addition of $90 million for preferred equity (50% of $180 million)[34] - Q2 debt stands at $6.3 billion[34]

Financial Performance - Adjusted EPS for Q2 2025 was $1.04, a 21% increase compared to $0.86 in Q2 2024[16, 24] - Adjusted Gross Margin for Q2 2025 reached $142.8 million, up 13% from Q2 2024[24] - Adjusted Net Income for Q2 2025 was $24.3 million, a 26% increase from Q2 2024[24] - Year-to-date Adjusted EPS reached $3.25, a 10% increase from YTD 2024[21, 25] - Year-to-date Adjusted Gross Margin was $325.2 million, up 12% from YTD 2024[25] - Year-to-date Adjusted Net Income was $75.4 million, a 14% increase from YTD 2024[25] Capital Expenditure and Projects - The company increased its 2025 capital expenditure guidance by $50 million, with a new range of $375 million to $425 million[17, 30] - A new Ohio pipeline project, with a capital investment of $10 million, will serve a fuel cell powering a data center and is expected to be operational in the first half of 2027[17, 44] - The Worcester Resiliency Upgrade (WRU) project, a $100 million FERC-approved LNG storage facility, is expected to add $3.9 million of additional full-year margin[46, 49, 50] Regulatory and Strategic Initiatives - Final orders were received for all three active rate cases in Delaware, Maryland, and Florida[17] - The company reaffirmed its 2025 Adjusted EPS guidance range of $6.15 to $6.35[30]

Financial Performance - The company generated Q2 2025 net revenue of $37.2 million and year-to-date 2025 net revenue of $76.1 million[9] - Acute Care franchise revenue grew by 55.5% for the three months ended June 30, 2025, compared to the same period last year[9] - The company achieved a record year-to-date 2025 adjusted EBITDA of $7.9 million[9] - Net product sales for Q2 2025 were $37.2 million, compared to $36.024 million in Q2 2024[32] - Adjusted EBITDA for Q2 2025 was $1.771 million, compared to $(1.234) million in Q2 2024[34] Product Performance - ZYNRELEF unit demand grew by 6.3% in Q2 2025 compared to Q1 2025[9] - APONVIE unit demand grew by 19% in Q2 2025 compared to Q1 2025[9] - Acute Care franchise net sales were $10.7 million for the three months ended June 30, 2025[14] - Oncology Care franchise net sales were $26.5 million for the three months ended June 30, 2025[26] Refinancing and Capital Structure - The company completed a comprehensive refinancing of prior debt facilities, reducing total debt from $175 million to $145 million and extending the bullet maturity to 2030+[9] - $110 million was funded at closing from Hercules Capital as a senior secured term loan[38] - $35 million of 50% Senior Convertible Notes were issued to Rubric Capital Management due in 2031[38]

Financial Performance - Revenue for Q2 2025 increased by 896% year-over-year to $3146 million from $1660 million in Q2 2024[52, 55] - Genomics revenue reached $2418 million, a 1153% increase compared to Q2 2024[55] - Data and Services revenue totaled $728 million, growing 357% year-over-year, with Insights (data licensing) growing 407%[55] - Gross profit improved by 1583% year-over-year, reaching $1950 million in Q2 2025[52, 55] - Adjusted EBITDA improved by 821%, with a loss of $(56) million in Q2 2025 compared to $(312) million in Q2 2024[52, 55] Genomics Business - Oncology testing (Tempus Genomics) revenue was $1332 million, up 329% year-over-year, with approximately 26% volume growth[55] - Hereditary testing (Ambry Genetics) contributed $973 million of revenue, up 336% year-over-year on a pro forma basis, with approximately 32% volume growth[55] - Average reimbursement per hereditary test was $760 in Q2 2025[24] Data and AI - Total Remaining Contract Value for Data and Services was >$940 million at the end of 2024[39] - Data Licensing Retention was ~140% at the end of 2024[39] - Tempus has >350 petabytes of rich multimodal healthcare data[12, 37]

Company Overview - China Yuchai International Limited (CYD) holds a 76.4% equity interest in Guangxi Yuchai Machinery Company Limited (GYMCL)[9] - Yuchai has a total engine production capacity of 600,000 units per annum[11] - Yuchai has over 3,000 domestic service stations throughout China[11] Market and Sales - China's GDP is targeted to grow approximately 5% for 2025[20] - In 2024, commercial vehicle industry unit sales reached 1 million, a YoY decrease of 9.9%[20] - In 2024, total truck sales increased by 15% YoY, with the HD segment accounting for 43% of total truck sales[24] - In 2024, total bus sales approximated 300,000 units, an increase of 28% YoY[24] - China Yuchai's total unit sales in 2024 (excluding NEV) were 344,486 units[31] Financial Performance - In 2024, the company's revenue reached RMB 19.1 billion[128] - The gross profit percentage in 2024 was 14.7%[136] - The profit after tax in 2024 was RMB 0.5 billion[136] - As of 2024, the company's cash and bank balance was RMB 6.4 billion[137] - In 2024, a share buyback was conducted for approximately US$ 39.8 million[142]

Financial Performance - The estimated combined risk-based capital (RBC) ratio is between 405% and 425%[9, 32] - The holding company liquid assets are $0.9 billion[9, 31] - The statutory combined total adjusted capital (TAC) is $5.6 billion[9] - The year-to-date normalized statutory loss is $0.1 billion[9] - Adjusted earnings were $198 million, $60 million below expectations, primarily due to a lower alternative investment income yield of 1.5%[9] Segment Performance - Annuities adjusted earnings, less notable items, were $332 million, an increase of 8% compared to 2Q 2024[12, 69] - Life Insurance adjusted earnings, less notable items, were $(26) million[17, 69] - Run-off adjusted earnings (loss), less notable items, were $(83) million[23, 69] - Corporate & Other adjusted earnings (loss), less notable items, were $(25) million[25, 69] Investment Portfolio - Total investments are $127 billion[36] - Fixed maturity securities (FMS) are $87 billion, with 97% investment grade[36] - Commercial mortgage loan portfolio is $12.9 billion, representing 10% of total investments[40]

Company Overview - Docebo's Annual Recurring Revenue (ARR) reached $2331 million as of June 30, 2025[18] - Subscription revenues accounted for 94% of the total revenue for the three months ended June 30, 2025[18] - The company boasts a customer base of 3,978 as of December 31, 2024[18] - Docebo experienced a 36% Subscription Revenue Compound Annual Growth Rate (CAGR) between fiscal year 2020 and fiscal year 2024[19] Market Opportunity - The total addressable market (TAM) for global learning is estimated at ~$30 billion, with customer experience (CX) accounting for 62% (~$185 billion) and employee experience (EX) for 38% (~$115 billion)[25] - The US Federal Government TAM is estimated at $12 billion, while the US SLED (State and Local Government Education) TAM is ~$27 billion[28] Financial Performance - Docebo generated approximately $60 million in cash since 2016 while growing ARR to $2331 million by the end of Q2 2025[103] - In Q2 2025, the subscription revenue growth was 145%[98] - The Adjusted EBITDA margin for Q2 2025 was 152%[102] - The Free Cash Flow margin for Q2 2025 was 187%[102] Customer Success - Brooks Automation reduced training costs by 20% using Docebo[63] - One customer training program saw 600,000+ registered users globally[66] - Another customer saved $15 million in training costs over 3 years[67]